Ayman El-Gawish

Ayman El-Gawish

Auto-generated profile, based on publicly available information

Ayman El-Gawish

Oral Medicine and Periodontology Department, Faculty of Dentistry, The British University in Egypt, El Sherouk City, Egypt

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2024 in Future Science OA
Verified
Journal Article
Open access
DGDalia Ghalwash
Dalia Ghalwash
AAAhmed Ammar
Ahmed Ammar
AAAsmaa Abou-Bakr
Asmaa Abou-Bakr
ADAl-Hassan Diab
Al-Hassan Diab
AEAyman El-Gawish
Ayman El-Gawish
The present study evaluated the sensitivity and specificity of important proteomic salivary biomarkers; IL-6, IL-8, and sCD44 in the early detection of oral cancer, and any possible associations with risk factors of oral cancer in an Egyptian population. The present investigation was conducted on 100 individuals; 25 healthy controls, 25 patients having oral potentially malignant disorders (OPMDs) with dysplasia; 25 patients having OPMDs without dysplasia, and 25 oral cancer patients. Demographic data modified gingival index, oral hygiene level, and salivary levels of the biomarkers were assessed. Salivary levels of IL-6, IL-8, and sCD44 progressively increased with increased disease severity. Salivary IL-8 and IL-6 levels possess a discriminating potential from normal tissue through different degrees of dysplasia to oral cancer, sCD44 levels had a discriminating power between normal and dysplastic tissues with high sensitivity and specificity. A positive correlation was found between the three biomarkers and the grade of oral squamous cell carcinoma (OSCC) and with different risk factors. This is the first study that evaluated multiple salivary proteomic biomarkers in the Egyptian population, and the results validate the ability of IL-6, IL-8, and sCD44 to be used as sensitive diagnostic and prognostic biomarkers for screening and early detection of oral cancer.

26 December 2024 in European Journal of Oral Sciences
Verified
Journal Article
Closed access
DGDalia Ghalwash
Dalia Ghalwash
AEAyman El‐Gawish
Ayman El‐Gawish
AAAhmed Ammar
Ahmed Ammar
AAAsmaa Abou-Bakr
Asmaa Abou-Bakr

13 October 2024 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
DGDalia Ghalwash
Dalia Ghalwash
AAAsmaa Abou-Bakr
Asmaa Abou-Bakr
AAAhmed Ammar
Ahmed Ammar
AMahmed hamdy mahmoud
ahmed hamdy mahmoud
AEAyman El-Gawish
Ayman El-Gawish
Aim: Burning mouth syndrome (BMS) is a debilitating chronic burning sensation in the oral cavity with no identifiable cause. The present research was conducted to evaluate the prevalence profile

15 May 2023 in International Journal of Dentistry
Verified
Journal Article
Open access
PDF file
RHRadwa R. Hussein
Radwa R. Hussein
EAEnji Ahmed
Enji Ahmed
AAAsmaa Abou-Bakr
Asmaa Abou-Bakr
AEAyman A. El-Gawish
Ayman A. El-Gawish
ARAbou-Bakr E. Ras
Abou-Bakr E. Ras
DGDalia Ghalwash
Dalia Ghalwash
Background. Coronavirus disease 2019 (COVID-19) has rapidly spread over the globe, and several oral symptoms have been documented. However, it is unclear whether these lesions are the result of coronavirus infection or are secondary symptoms of the patients systemic illness. The aim of this study was to collect data from various hospitals on COVID-19 patients with oral involvement in order to highlight different oral changes that may be manifested in those patients. Methods. This observational cross-sectional multicenter study used an online questionnaire covering oral signs and symptoms that were believed to be related to COVID-19 patients who were hospitalized in different hospitals in Egypt. Results. 94.3 of the 210 patients who participated in the current study developed oral symptoms. Altered taste sensation (56.2), burning sensation (43.3), and oral candidiasis (40) were the most prevalent oral symptoms (34.4) that were found in the studied sample. Conclusions. COVID-19 has a major influence on the oral cavity, with numerous oral symptoms that may impair quality of life. Thus, considering the need for support, pain control, and management for a better prognosis, the clinical dental evaluation of hospitalized patients with infectious diseases like COVID-19 should be addressed.

29 December 2025 in The Egyptian Journal of Otolaryngology
Verified
Journal Article
Open access
PDF file
DGDalia Ghalwash
Dalia Ghalwash
AEAyman El-Gawish
Ayman El-Gawish
AAAsmaa Abou-Bakr
Asmaa Abou-Bakr
Background: The current investigation aimed to assess the prevalence of xerostomia, its relation to risk factors, and its impact on the quality of life among a sample of the Egyptian population. Methods: This cross-sectional study collected data on the occurrence of xerostomia and risk factors from 1220 subjects in several Egyptian governorates, including sex, age, smoking, systemic illness, and medications. Subjective and objective dry mouth scores, taste disturbances, burning sensations, and their impact on quality of life were assessed. Results: Xerostomia was estimated to involve 49.6% of the studied population. It was found to increase with age and was substantially higher amongst females. Xerostomia was significantly associated with systemic disorders such as diabetes and hypertension. Taste disturbances affected 49.2%, and burning sensation was reported by 76.1% of xerostomia cases; around 81% of cases reported moderate to extreme impact of xerostomia on their quality of life. Additionally, a statistically significant correlation was found between xerostomia and age ( p = 0.025 * ), gender ( p = 0.018 * ), medical condition ( p = 0.016 * ), long-term medication ( p = 0.037 * ), burning sensation ( p = 0.012 * ), taste disturbance ( p = 0.031 * ), and the impact on quality of life ( p = 0.016 * ). Conclusions: The occurrence of xerostomia was high among the Egyptian population, especially amongst older females, having a significant impact on quality of life, and was significantly associated with several systemic diseases that are commonly encountered in Egypt.

1 January 2025 in International Journal of Dentistry
Verified
Journal Article
Open access
DGDalia Ghalwash
Dalia Ghalwash
AAAhmed Ammar
Ahmed Ammar
AMahmed hamdy mahmoud
ahmed hamdy mahmoud
AEAyman El-Gawish
Ayman El-Gawish
Aims: The present study aspired to evaluate the impact of the adjunctive use of omega‐3 with nonsurgical periodontal therapy on clinical parameters as well as local and systemic chemerin levels as a marker of cardiovascular disease risk in periodontitis patients with diabetes. Methods: This randomized clinical trial was performed on thirty periodontitis patients with type II diabetes divided into two equal groups, both treated by nonsurgical periodontal treatment with the adjunctive use of daily 1000 mg Omega‐3FAs in group I only for 6 months. Patients were reexamined after 2 weeks (baseline), 3, and 6 months for recording the clinical parameters as follows: plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment loss (CAL). Chemerin levels were assessed in both serum and GCF samples, HbA1c levels were also assessed. Results: Omega‐3FAs‐treated group recorded a more statistically significant improvement in clinical parameters compared to the control group, particularly concerning PD and CAL. A statistically significant reduction of HbA1c levels between baseline, 3 and 6 m values was encountered in Omega‐3FAs treated group, while no significant difference was evident in the control group. Additionally, Omega‐3FAs treated group recorded a more statistically significant reduction of GCF and serum chemerin levels in comparison to the control group after 6 months of therapy. Conclusion: The adjunctive use of omega‐3FAs with nonsurgical periodontal therapy has resulted in significant improvement of clinical periodontal parameters and glycemic control in periodontitis patients with type II diabetes, alongside the additional benefit of reducing both local and systemic chemerin levels, a biomarker for cardiovascular risk. Trial Registration: Clinical Trial Registry identifier: NCT06463535